Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
MoonLake Immunotherapeutics - Class A Ordinary Shares
(NQ:
MLTX
)
49.43
+0.10 (+0.20%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MoonLake Immunotherapeutics - Class A Ordinary Shares
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
June 10, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 16, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
April 10, 2024
From
Komodo Health
Via
Business Wire
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
March 10, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
March 04, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
February 26, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
November 05, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
October 15, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
October 11, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
September 06, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
July 25, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MarketBeat Week in Review – 6/26 - 6/30
July 01, 2023
Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
MoonLake Immunotherapeutics Makes a Moonshot on Trials
June 28, 2023
Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results.
Via
MarketBeat
Exposures
Product Safety
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
June 28, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of Phase 2 Trial
June 26, 2023
Via
Investor Brand Network
MoonLake Immunotherapeutics (NASDAQ: MLTX) Announces Breakthrough Results for Sonelokimab in Phase 2 Trial
June 26, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) has made significant strides with the successful outcome of their Phase 2 MIRA trial for sonelokimab,
Via
Spotlight Growth
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
June 25, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
April 19, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.